Povezanost polimorfizama gena TP53 i CYP2E1*5B s nemikrocelularnim karcinomom pluća
Ahmet Oguz Ada
; Department of Toxicology, Faculty of Pharmacy, University of Ankara, Ankara, Turkey
Serdar Bilgen
; Department of Toxicology, Faculty of Pharmacy, University of Ankara, Ankara, Turkey
Volkan Karacaoglan
; Department of Toxicology, Faculty of Pharmacy, University of Ankara, Ankara, Turkey
Celalettin Semih Kunak
; Department of Toxicology, Faculty of Pharmacy, University of Ankara, Ankara, Turkey
Emre Soydas
; Department of Toxicology, Faculty of Pharmacy, University of Ankara, Ankara, Turkey
Sibel Alpar
; Ataturk Pulmonary Diseases and Thoracic Surgery Hospital, Ankara, Turkey
Meral Gulhan
; Ataturk Pulmonary Diseases and Thoracic Surgery Hospital, Ankara, Turkey
Mumtaz Iscan
; Department of Toxicology, Faculty of Pharmacy, University of Ankara, Ankara, Turkey
APA 6th Edition Oguz Ada, A., Bilgen, S., Karacaoglan, V., Semih Kunak, C., Soydas, E., Alpar, S., ... Iscan, M. (2016). Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer. Arhiv za higijenu rada i toksikologiju, 67 (4), 311-316. https://doi.org/10.1515/aiht-2016-67-2812
MLA 8th Edition Oguz Ada, Ahmet, et al. "Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer." Arhiv za higijenu rada i toksikologiju, vol. 67, br. 4, 2016, str. 311-316. https://doi.org/10.1515/aiht-2016-67-2812. Citirano 05.03.2021.
Chicago 17th Edition Oguz Ada, Ahmet, Serdar Bilgen, Volkan Karacaoglan, Celalettin Semih Kunak, Emre Soydas, Sibel Alpar, Meral Gulhan i Mumtaz Iscan. "Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer." Arhiv za higijenu rada i toksikologiju 67, br. 4 (2016): 311-316. https://doi.org/10.1515/aiht-2016-67-2812
Harvard Oguz Ada, A., et al. (2016). 'Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer', Arhiv za higijenu rada i toksikologiju, 67(4), str. 311-316. https://doi.org/10.1515/aiht-2016-67-2812
Vancouver Oguz Ada A, Bilgen S, Karacaoglan V, Semih Kunak C, Soydas E, Alpar S i sur. Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer. Arh Hig Rada Toksikol. [Internet]. 2016 [pristupljeno 05.03.2021.];67(4):311-316. https://doi.org/10.1515/aiht-2016-67-2812
IEEE A. Oguz Ada, et al., "Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer", Arhiv za higijenu rada i toksikologiju, vol.67, br. 4, str. 311-316, 2016. [Online]. https://doi.org/10.1515/aiht-2016-67-2812
Sažetak Nemikrocelularni karcinom pluća (engl. non-small cell lung cancer – NSCLC) najčešći je oblik karcinoma pluća. Polimorfizimi gena za supresiju tumora i gena koji kodiraju enzime za razgradnju ksenobiotika mijenjaju aktivnost tih gena te značajno utječu na individualnu sklonost nastanku NSCLC-a. Budući da u literaturi nema dovoljno saznanja o njihovu utjecaju na nastanak bolesti, cilj je ovoga ispitivanja bio utvrditi povezanost polimorfizama tumorskoga supresorskoga gena TP53 (Arg72Pro), odnosno gena CYP2E1*5B za metabolizam ksenobiotika, s rizikom od NSCLC-a. Ispitivanje je obuhvatilo 172 bolesnika s NSCLC-om i 172 kontrolna ispitanika (po 156 muškaraca i 16 žena u svakoj skupini). Genski su polimorfizmi utvrđeni polimeraznom lančanom reakcijom u stvarnom vremenu (engl. real-time polymerase chain reaction – RT-PCR) te kombinacijom PCR-a s metodom cijepanja DNA restrikcijskim enzimima (engl. restriction fragment length polymorphism – PCR-RFLP). Multivarijantna analiza upozorava na značajnu povezanost kombinacije TP53 kodon72 Arg/Pro i Pro/Pro genotipova s NSCLC-om (OR 2,21; 95 % CI 1,39-3,51; p=0,001). Također je analizirana povezanost kombinacija ovih genskih varijanta s polimorfizmima gena glutation S-tranferaze GSTM1, GSTT1, GSTP1 ekson 5 (Ile105Val) i GSTP1 ekson 6 (Ala114Val) s rizikom od NSCLC-a te utvrđeno značajno povećanje rizika kod sljedećih kombinacija: TP53 kodon72 s GSTM1 nula (OR 2,22; 95 % CI 1,23-4,04; p=0,009), GSTT1 nula (OR 2,98; 95 % CI 1,49-5,94; p=0,002) i GSTP1 (Ala114Val) (OR 3,38; 95 % CI 1,54-7,41; p=0,002). Da bi se potvrdili ovi preliminarni rezultati, potrebna su istraživanja na većim uzorcima.